13,521 Shares in AbCellera Biologics Inc. (NASDAQ:ABCL) Purchased by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. acquired a new stake in AbCellera Biologics Inc. (NASDAQ:ABCL) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 13,521 shares of the company’s stock, valued at approximately $40,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Northern Trust Corp boosted its holdings in shares of AbCellera Biologics by 106.9% in the fourth quarter. Northern Trust Corp now owns 81,621 shares of the company’s stock valued at $239,000 after purchasing an additional 42,174 shares during the period. Boothbay Fund Management LLC purchased a new stake in shares of AbCellera Biologics in the 4th quarter worth $46,000. Capital World Investors bought a new position in shares of AbCellera Biologics during the 4th quarter worth $23,245,000. PEAK6 LLC bought a new position in shares of AbCellera Biologics during the 4th quarter worth $586,000. Finally, XTX Topco Ltd purchased a new position in shares of AbCellera Biologics during the fourth quarter valued at $269,000. 61.42% of the stock is currently owned by institutional investors.

AbCellera Biologics Price Performance

Shares of ABCL stock opened at $2.02 on Tuesday. The stock’s 50-day moving average is $2.29 and its 200 day moving average is $2.71. AbCellera Biologics Inc. has a 1-year low of $1.89 and a 1-year high of $4.34. The company has a market cap of $602.82 million, a P/E ratio of -3.31 and a beta of 0.46.

AbCellera Biologics (NASDAQ:ABCL) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.02. The firm had revenue of $4.24 million during the quarter, compared to analyst estimates of $7.12 million. AbCellera Biologics had a negative net margin of 533.32% and a negative return on equity of 15.73%. On average, analysts anticipate that AbCellera Biologics Inc. will post -0.59 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Truist Financial lowered their price objective on shares of AbCellera Biologics from $28.00 to $10.00 and set a “buy” rating for the company in a research note on Friday. KeyCorp upped their price target on shares of AbCellera Biologics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 16th. Stifel Nicolaus dropped their price objective on shares of AbCellera Biologics from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Finally, Benchmark reissued a “hold” rating on shares of AbCellera Biologics in a research note on Monday, March 3rd.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.